血浆GFAP与UCH-L1在GCS 13-15分TBI患者中识别颅内病变的临床截断值:TRACK-TBI研究
该研究基于TRACK-TBI前瞻性数据,纳入1718例GCS 13-15分TBI患者,分析伤后24小时内血浆GFAP和UCH-L1对CT或MRI颅内病变的识别能力。结果显示GFAP对CT+的AUC为0.82,UCH-L1为0.60;GFAP在CT+患病率0.36和0.1时达到调整PPV 0.9的截断值分别为2879和5191 pg/mL。结论提示这些阈值可用于辅助诊断和分诊。
要点
- GFAP对CT+的AUC为0.82,优于UCH-L1的0.60。
- CT+患病率0.36时,GFAP截断值2879 pg/mL可达调整PPV 0.9。
- CT阴性者中GFAP预测MRI+的AUC为0.76,截断值1382 pg/mL对应PPV 0.9。
核心结论
- GFAP截断值可用于辅助识别GCS 13-15分TBI患者的颅内病变并指导分诊。
- UCH-L1对CT+和MRI+的判别能力均较低(AUC 0.60)。
研究设计与样本
- TRACK-TBI研究的事后分析,前瞻性纵向观察性研究,纳入18家美国一级创伤中心24小时内就诊的TBI患者。
- 共1718例GCS 13-15分患者,伤后24小时内采血检测GFAP和UCH-L1。
主要发现
- 1718例中633例(37%)CT+;1085例CT-者中608例伤后2周接受MRI,154例(25%)MRI+。
- GFAP判别CT+ vs CT-的AUC为0.82(95%CI 0.80-0.84),UCH-L1为0.60(95%CI 0.57-0.63)。
- GFAP判别CT-/MRI+ vs CT-/MRI-的AUC为0.76(95%CI 0.71-0.81),UCH-L1为0.60(95%CI 0.55-0.65)。
关键数值与推荐
- CT+预测:假设患病率0.36,调整PPV 0.9时GFAP中位截断值为2879 pg/mL(95%CI 2195-4704)。
- CT+预测:假设患病率0.1,调整PPV 0.9时GFAP中位截断值为5191 pg/mL(95%CI 3779-5426)。
- GCS 13-15且CT-者MRI+预测:调整PPV 0.9时GFAP中位截断值为1382 pg/mL(95%CI 1145-2424)。
- GCS 13-15且CT-者MRI+预测:调整PPV 0.98时GFAP中位截断值为2317 pg/mL(95%CI 1262-2551 pg/mL)。
临床怎么用
- GFAP截断值可作为辅助诊断工具,帮助决定GCS 13-15分TBI患者是否需要紧急神经影像和升级治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The authors sought to identify plasma glial fibrillary acidic protein (GFAP) and ubiquitin c-terminal hydrolase-L1 (UCH-L1) cutoffs corresponding to a range of high positive predictive values (PPVs) for detecting intracranial pathology on CT and detecting pathology on MRI (when CT is negative) in patients who present to a level I trauma center for TBI evaluation with Glasgow Coma Scale (GCS) scores of 13-15. METHODS: This is a secondary analysis of prospectively collected data from the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study, which is a longitudinal, observational study of patients with TBI who presented to one of 18 US level I trauma centers within 24 hours of injury. Blood samples were collected within 24 hours. Plasma samples were analyzed for GFAP (pg/mL) and UCH-L1 (pg/mL). The CT or MRI scan was considered positive (CT+, MRI+) if there was evidence of acute intracranial pathology related to TBI. Receiver operating characteristic curve analysis (AUC) was performed to evaluate the ability of day-1 GFAP and UCH-L1 to discriminate CT+ versus CT-, and CT-/MRI+ versus CT-/MRI-. A K-fold cross-validation procedure was used to identify GFAP cutoffs for predicting CT+ among patients with GCS scores of 13-15 and for predicting MRI+ among patients with GCS scores of 13-15 and CT- subjects, based on the adjusted PPV thresholds. RESULTS: Among the 1718 TBI participants with GCS scores 13-15, 633 (37%) had CT+ findings. Of the 1085 CT- participants, 608 underwent MRI at 2 weeks postinjury, of whom 154 (25%) had MRI+ findings. Day-1 GFAP had an area under the curve (AUC) of 0.82 (95% CI 0.80-0.84), and UCH-L1 had an AUC of 0.60 (95% CI 0.57-0.63) for discriminating CT+ from CT-. Day-1 GFAP had an AUC of 0.76 (95% CI 0.71-0.81) while UCH-L1 had an AUC of 0.60 (95% CI 0.55-0.65) for discriminating CT-/MRI+ from CT-/MRI-. For CT+ prediction, assuming a prevalence of 0.36 (from our data) and 0.1 (from the literature), the median GFAP cutoffs to achieve an adjusted PPV of 0.9 were 2879 (95% CI 2195-4704) and 5191 (95% CI 3779-5426), respectively. For MRI+ prediction among GCS 13-15 CT- patients, the median GFAP cutoffs were 1382 (95% CI 1145-2424) to achieve an adjusted PPV of 0.9 and 2317 pg/mL (95% CI 1262-2551 pg/mL) to achieve an adjusted PPV of 0.98. CONCLUSIONS: These threshold values can be used as an aid-in-diagnosis tool and assist in appropriate triaging of patients who have sustained TBI to urgent neuroimaging, potential escalation in care, and interventions as clinically indicated.
引用
- Eagle SR, Yue JK, Puccio AM, et al. Clinical cutoffs for plasma biomarkers to identify intracranial pathology in traumatic brain injury patients with Glasgow Coma Scale scores 13 to 15: a TRACK-TBI study. J Neurosurg. 2026. PMID: 42913506. doi:10.3171/2026.3.JNS252691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。